AU2002317169A1 - Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases - Google Patents

Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases

Info

Publication number
AU2002317169A1
AU2002317169A1 AU2002317169A AU2002317169A AU2002317169A1 AU 2002317169 A1 AU2002317169 A1 AU 2002317169A1 AU 2002317169 A AU2002317169 A AU 2002317169A AU 2002317169 A AU2002317169 A AU 2002317169A AU 2002317169 A1 AU2002317169 A1 AU 2002317169A1
Authority
AU
Australia
Prior art keywords
diagnosis
gene
indication
expression
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002317169A
Inventor
Dave Brett
Wolfgang Kemmner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of AU2002317169A1 publication Critical patent/AU2002317169A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002317169A 2001-05-31 2002-05-30 Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases Abandoned AU2002317169A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2001126472 DE10126472A1 (en) 2001-05-31 2001-05-31 Use of the detection of the expression of splice variants of Gen21 for the diagnosis and therapy of tumor diseases
DE10126472.0 2001-05-31
PCT/DE2002/002001 WO2002097119A2 (en) 2001-05-31 2002-05-30 Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases

Publications (1)

Publication Number Publication Date
AU2002317169A1 true AU2002317169A1 (en) 2002-12-09

Family

ID=7686732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002317169A Abandoned AU2002317169A1 (en) 2001-05-31 2002-05-30 Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases

Country Status (3)

Country Link
AU (1) AU2002317169A1 (en)
DE (1) DE10126472A1 (en)
WO (1) WO2002097119A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578762A4 (en) * 2002-11-12 2006-08-02 Wyeth Corp A novel pth responsive gene

Also Published As

Publication number Publication date
WO2002097119A3 (en) 2003-05-30
WO2002097119A2 (en) 2002-12-05
DE10126472A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
IL157364A0 (en) Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1
AU2002254615A1 (en) Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
AU2003268268A1 (en) Guide catheter for introduction into the subarachnoid space and methods of use thereof
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
AU2002240336A1 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2002306600A1 (en) Sperm protein 17 for the diagnosis and treatment of cancer
AU2002317169A1 (en) Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU2002364757A1 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
AU2002251367A1 (en) Proteins and genes for diagnosis and treatment of erbb2-related cancer
GB9908059D0 (en) Diagnosis and treatment of diseases
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours
AU1040700A (en) The genetic determination of genes and its use for the prophylaxis and therapy of diseases
AU2002332606A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002240745A1 (en) Diagnosis and treatment of blood disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase